Mark J. Gergen
2021 - Poseida Therapeutics
In 2021, Mark J. Gergen earned a total compensation of $2.8M as Chief Executive Officer and President and former Chief Business Officer at Poseida Therapeutics, a 96% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $187,450 |
|---|---|
| Option Awards | $2,164,381 |
| Salary | $462,833 |
| Other | $9,252 |
| Total | $2,823,916 |
Gergen received $2.2M in option awards, accounting for 77% of the total pay in 2021.
Gergen also received $187.5K in non-equity incentive plan, $462.8K in salary and $9.3K in other compensation.
Rankings
In 2021, Mark J. Gergen's compensation ranked 4,663rd out of 12,405 executives tracked by ExecPay. In other words, Gergen earned more than 62.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,663 out of 12,405 | 62nd |
Division Manufacturing | 1,932 out of 5,494 | 65th |
Major group Chemicals And Allied Products | 807 out of 2,369 | 66th |
Industry group Drugs | 720 out of 2,090 | 66th |
Industry Biological Products, Except Diagnostic Substances | 182 out of 452 | 60th |
Source: SEC filing on April 27, 2022.
Gergen's colleagues
We found three more compensation records of executives who worked with Mark J. Gergen at Poseida Therapeutics in 2021.